Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant MRG003 + Pucotenlimab in OSCC
NCT07766889Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Sep 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
A Phase 2 trial of becotatug vedotin, pucotenlimab in oral cavity squamous cell carcinoma (OCSCC), sponsored by Sun Yat-sen University. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
becotatug vedotinpucotenlimab
03
Conditions
oral cavity squamous cell carcinoma (OCSCC)
Beyond the preview
Go deeper on NCT07766889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07766889.